last
decad
poxvir
vector
emerg
mainstay
approach
induct
cellmedi
immun
vaccin
suitabl
human
use
led
widespread
clinic
test
candid
vector
infecti
intracellular
pathogen
cancer
contrast
poxvirus
wide
perceiv
vaccin
field
poor
choic
vector
induct
humor
immun
howev
grow
bodi
data
anim
model
recent
clinic
trial
suggest
vector
success
util
prime
boost
b
cell
effect
antibodi
respons
signific
progress
made
context
heterolog
primeboost
immun
regim
wherebi
poxvirus
abl
boost
respons
prime
vector
lead
induct
hightitr
antigenspecif
antibodi
respons
case
poxvir
vector
shown
stimul
humor
immun
encod
transgen
particular
viral
surfac
protein
influenza
haemagglutinin
veterinari
field
recombin
poxvir
vector
made
signific
impact
numer
vector
licens
use
varieti
anim
virus
ongo
studi
continu
explor
potenti
poxvir
vector
modul
qualit
aspect
humor
respons
well
amen
adjuvant
seek
improv
quantit
antibodi
immunogen
nevertheless
underli
mechan
b
cell
induct
recombin
poxvirus
remain
poorli
defin
work
necessari
help
guid
ration
optim
futur
poxvir
vaccin
candid
aim
induc
antibodi
vaccin
remain
cornerston
control
prevent
infecti
diseas
human
anim
recent
time
wit
dramat
reduct
burden
diseas
whole
rang
licens
product
effect
deploy
well
first
mass
vaccin
campaign
lead
erad
two
infecti
organ
variola
viru
caus
agent
smallpox
rinderpest
viral
diseas
cattl
today
new
improv
nextgener
product
remain
intens
develop
third
pathogen
poliomyel
viru
stand
brink
erad
although
develop
everi
effect
vaccin
taken
extens
effort
overcom
uniqu
seri
challeng
much
success
rest
abil
vaccin
formul
consist
killedliveattenu
virus
bacteria
well
recombin
subunit
protein
vaccin
formul
adjuv
elicit
robust
protect
level
immun
latter
turn
reli
remark
natur
humor
arm
adapt
immun
system
gener
effect
polyclon
antibodi
respons
associ
longterm
mainten
b
cell
immunolog
memori
howev
despit
laudabl
success
mani
challeng
remain
estim
world
health
organ
million
death
per
annum
still
occur
worldwid
due
infecti
diseas
approxim
million
vaccineprevent
highlight
urgenc
face
work
acceler
deploy
exist
vaccin
howev
signific
major
remain
due
human
pathogen
licens
highli
effect
vaccin
avail
includ
socal
big
three
plasmodium
malaria
parasit
mycobacterium
tuberculosi
human
immunodefici
mani
socal
difficult
pathogen
develop
attenu
whole
organ
vaccin
may
unfeas
due
safeti
concern
limit
technolog
challeng
relat
product
organ
case
subunit
vaccin
strategi
struggl
face
signific
antigen
polymorph
lack
knowledg
protect
target
immun
highli
complex
pathogen
mani
case
protect
immun
mechan
may
also
constitut
simpl
threshold
level
neutral
antibodi
necessit
complex
interplay
cellular
immun
system
understand
remain
limit
abil
induc
vaccin
even
licens
vaccin
thought
protect
via
cellmedi
immun
notabl
attenu
bovi
bacil
bcg
use
year
vaccin
human
tuberculosi
tb
variabl
level
efficaci
primarili
dissemin
tb
childhood
much
research
therefor
focuss
last
decad
novel
altern
vaccin
strategi
aim
induct
strong
cellmedi
immun
intracellular
pathogen
well
cancer
context
recombin
attenu
poxvir
vector
emerg
frontrun
deliveri
platform
intens
research
cell
vaccin
field
highlight
robust
util
poxvir
subunit
vaccin
platform
larg
transgen
insert
capac
kbp
scope
inclus
multipl
transgen
vivo
mammalian
express
foreign
antigen
circumv
need
heterolog
express
difficult
recombin
protein
absenc
requir
formul
classic
adjuv
rel
eas
gener
new
recombin
includ
use
bac
technolog
well
scaleup
product
process
compliant
good
manufactur
practic
gmp
excel
safeti
track
record
attenu
poxvir
vector
human
use
lead
favour
outlook
regulatori
agenc
light
advantag
come
littl
surpris
platform
also
explor
induct
humor
immun
alongsid
intens
effort
focuss
cell
induct
progress
former
endeavour
focu
review
mani
year
poxvirus
wide
perceiv
subunit
vaccin
field
poor
choic
vector
induct
humor
immun
somewhat
surpris
given
track
record
vaccin
agent
smallpox
live
replic
vaccinia
although
origin
dryvax
vaccin
smallpox
polyclon
mixtur
vaccinia
virus
produc
skin
calv
longer
manufactur
recent
effort
led
secondgener
product
human
use
tm
plaquepurifi
deriv
dryvax
asept
propag
cell
cultur
studi
mice
shown
induct
strong
celldepend
neutral
antibodi
respons
respons
live
replic
vaccinia
viru
vaccin
peak
one
month
maintain
past
three
month
similar
result
observ
rhesu
macaqu
whilst
human
follow
vaccinia
immun
neutral
antibodi
detect
within
day
rais
intracellular
matur
virion
imv
extracellular
envelop
viru
eev
form
peak
respons
declin
first
year
stabil
report
halflif
year
similar
replic
viral
infect
analyz
longitudin
studi
manner
vacciniaspecif
igg
memori
b
cell
appear
maintain
year
analysi
proteom
array
vaccinia
viru
gene
identifi
antigen
recogn
vaccin
human
serum
mice
includ
surfac
protein
imv
eev
well
core
protein
solubl
factor
amongst
report
neutral
determin
human
sera
mous
model
shown
passiv
transfer
immun
serum
monoclon
antibodi
protect
vaccinia
viru
challeng
similar
result
obtain
cell
deplet
although
antivir
cell
respons
still
contribut
immun
b
cell
defici
model
eleg
studi
rhesu
macaqu
sinc
confirm
observ
wherebi
deplet
b
cell
immun
monkey
abrog
protect
efficaci
contrast
cell
deplet
fail
affect
lethal
monkeypox
viru
challeng
outcom
conclus
demonstr
antibodi
suffici
protect
lethal
infect
shown
follow
surviv
monkey
administ
human
vaccinia
immun
globulin
vig
four
day
prior
challeng
similar
document
case
human
show
highli
success
outcom
follow
vig
transfer
smallpoxinfect
patient
arguabl
howev
modern
subunit
vaccin
develop
potenti
discourag
strong
antipoxvir
vector
immun
seek
instead
strong
respons
transgen
encod
recombin
viru
success
regard
first
demonstr
recombin
vaccinia
viru
vaccin
report
encod
hepat
b
surfac
antigen
hbsag
vector
induc
antibodi
respons
encod
transgen
suffici
protect
chimpanze
hepat
b
challeng
sinc
report
first
antibodyinduc
poxvir
vector
vaccin
thirti
year
ago
key
breakthrough
demonstr
replicationcompet
vector
immunogen
necessarili
go
hand
hand
intens
effort
therefor
focuss
util
relat
attenu
poxvir
vector
aim
maintain
immunolog
robust
whilst
maxim
safeti
rang
attenu
poxvir
vaccin
vector
avail
includ
vector
demonstr
safeti
record
human
use
wide
use
includ
attenu
orthopoxviru
cousin
vaccinia
modifi
vaccinia
viru
ankara
mva
well
new
york
attenu
vaccinia
nyvac
field
attenu
avipoxvirus
also
develop
includ
fowlpox
strain
canarypox
alvac
mva
attenu
parent
chorioallantoi
vaccinia
viru
ankara
cva
serial
passag
chick
embryo
fibroblast
cef
lead
signific
delet
genom
loss
abil
replic
mammalian
cell
except
transform
cell
line
nyvac
gener
genet
delet
open
read
frame
copenhagen
strain
vaccinia
lead
replic
defici
mice
mount
signific
dosedepend
antimva
neutral
antibodi
respons
compar
replicationcompet
vaccinia
higher
dose
immun
viru
requir
respons
mount
imv
eev
form
like
contribut
protect
efficaci
lethal
intranas
challeng
western
reserv
wr
strain
vaccinia
given
signific
safeti
issu
case
lifethreaten
health
risk
surround
use
live
vaccinia
smallpox
vaccin
surpris
attenu
orthopoxvirus
explor
third
gener
vaccin
candid
especi
light
ongo
concern
surround
bioterror
current
mva
advanc
version
call
imvamun
develop
bavarian
nordic
fast
track
licensur
usa
attenu
virus
deriv
lister
vaccinia
strain
remain
develop
interestingli
fourth
gener
subunit
vaccin
base
neutral
antibodi
determin
imv
eev
form
shown
compar
better
efficaci
mva
protect
studi
lethal
monkeypox
viru
challeng
nonhuman
primat
model
serum
monkey
vaccin
subunit
vaccin
candid
could
passiv
transfer
immun
mice
confirm
critic
role
antibodi
protect
recombin
attenu
orthopoxvirus
also
shown
compar
immunogen
replicationcompet
vaccinia
numer
anim
studi
although
focuss
cell
respons
encod
transgen
assess
antibodi
induct
comparison
mva
wr
vaccinia
mice
compar
induct
antibodi
vaccinia
antigen
well
transgen
shown
although
higher
dose
mva
requir
studi
shown
recombin
mva
vector
immunogen
antibodi
induct
includ
vector
encod
solubl
glycoprotein
b
gb
human
cytomegaloviru
hcmv
control
modifi
promot
delet
iii
locu
case
strong
neutral
antibodi
respons
induc
gb
mice
follow
two
immun
given
either
intramuscularli
subcutan
maintain
six
month
could
boost
vaccin
readministr
timepoint
highli
compar
result
also
report
mice
guinea
pig
alvac
vector
recombin
antigen
similarli
recombin
mva
encod
spike
glycoprotein
sever
acut
respiratori
syndrom
sar
coronaviru
delet
iii
locu
shown
induc
neutral
antibodi
two
intramuscular
immun
mice
rabbit
rhesu
macaqu
latter
protect
pathogen
challeng
mva
also
shown
promis
antibodyinduc
vaccin
anoth
viral
surfac
protein
haemagglutinin
ha
influenza
viru
almost
year
ago
mva
recombin
ha
intern
nucleoprotein
np
antigen
shown
confer
protect
lethal
homolog
strain
influenza
infect
mice
follow
intramuscular
inject
similar
result
ten
year
earlier
recombin
vaccinia
viru
mva
vaccin
coexpress
antigen
induc
strong
haemagglutin
inhibit
hi
titr
well
cytotox
cell
respons
discuss
earlier
perform
compar
better
wr
vaccinia
encod
antigen
latter
case
antiha
respons
associ
protect
separ
studi
mice
well
ferret
recent
mva
vector
encod
ha
subtyp
influenza
report
mice
cynomolgu
macaqu
twodos
immun
regim
shown
induc
strong
protect
antibodi
respons
crossreact
heterolog
strain
similar
result
also
shown
ha
encod
mva
vector
follow
singl
immun
balbc
mice
mva
vaccin
encod
ha
type
pandem
influenza
also
shown
robust
antibodi
respons
follow
two
immun
ferret
well
protect
immun
challeng
heterolog
strain
similar
result
report
mice
better
efficaci
report
mva
vector
encod
ha
rather
neuraminidas
na
despit
highli
promis
result
describ
antibodi
induct
poxvir
vector
recombin
viral
surfac
protein
antigen
fare
well
poxvir
deliveri
system
tradit
approach
util
induct
hightitr
antibodi
respons
subunit
vaccin
recombin
proteininadjuv
formul
technolog
perform
robustli
wide
rang
candid
antigen
although
reli
heavili
heterolog
express
system
protein
antigen
product
well
access
suitabl
adjuv
mani
difficult
pathogen
howev
malaria
parasit
heterolog
product
antigen
tradit
express
system
escherichia
coli
prove
extrem
challeng
similarli
access
proprietari
adjuv
potent
demonstr
accept
reactogen
profil
human
equal
problemat
mani
diseas
poverti
prospect
antibodi
induct
use
vector
vaccin
technolog
therefor
appeal
given
aforement
advantag
coupl
known
capabl
induct
strong
cellular
immun
unlik
proteinbas
vaccin
inde
increasingli
anticip
induct
strong
cellular
immun
conjunct
antibodi
may
essenti
protect
challeng
viral
bacteri
parasit
pathogen
vaccin
current
exist
develop
viral
vector
vaccin
capabl
induc
antibodi
wide
studi
field
bloodstag
malaria
asexu
bloodstag
malaria
parasit
lifecycl
see
exponenti
growth
parasit
number
within
host
respons
associ
morbid
mortal
vaccin
develop
aim
induc
neutral
antibodi
prevent
infect
new
host
red
blood
cell
invas
merozoit
form
parasit
earli
studi
use
lead
candid
bloodstag
malaria
antigen
kda
cterminu
merozoit
surfac
protein
show
littl
detect
antibodi
induct
follow
immun
balbc
mice
recombin
mva
vector
case
mva
antigen
insert
thymidin
kinas
tk
locu
control
earlyl
promot
antigen
present
termin
repeat
region
genom
control
promot
contrast
shown
singl
immun
mice
recombin
human
adenoviru
serotyp
vaccin
could
induc
specif
serum
igg
respons
wherea
mva
ineffici
prime
adenovirusprim
respons
could
significantli
boost
recombin
mva
administ
eight
week
later
regim
first
vector
vaccin
platform
demonstr
hightitr
antibodi
respons
mice
shown
protect
lethal
challeng
bloodstag
p
yoelii
rodent
malaria
parasit
heterolog
dna
vaccin
primemva
boost
regim
employ
antigen
show
much
lower
level
igg
induct
whilst
heterolog
poxviru
regim
show
detect
antibodi
consist
poor
antibodi
prime
poxvirus
report
anoth
studi
vector
malaria
vaccin
numer
followup
studi
shown
adenoviru
primepoxviru
boost
approach
versatil
robust
regard
antibodi
induct
encod
transgen
malaria
field
vaccin
develop
target
bloodstag
antigen
apic
membran
antigen
well
lead
mosquitostag
transmissionblock
antigen
clinic
vaccin
encod
human
malaria
parasit
p
falciparum
util
simian
adenoviru
prime
chimpanze
adenoviru
mva
boost
wide
test
mice
rabbit
rhesu
macaqu
demonstr
strong
function
antibodi
induct
similar
data
relat
abil
poxvir
vaccin
boost
antibodi
respons
follow
malaria
field
vaccin
develop
recent
studi
rhesu
macaqu
show
regim
afford
signific
protect
highli
stringent
simian
immunodefici
viru
siv
challeng
antibodi
titr
encod
envelop
env
transgen
shown
associ
vaccin
efficaci
partial
efficaci
mediat
antienv
antibodi
also
report
siv
challeng
follow
mva
boost
dna
vaccin
prime
respons
antienv
loop
antibodi
also
report
mice
prime
recombin
influenza
viru
follow
boost
mva
wr
vaccinia
highest
respons
seen
mva
recent
vector
vaccin
platform
shown
key
advantag
regard
antigenscreen
wherebi
p
falciparum
reticulocyt
bind
protein
homologu
identifi
first
bloodstag
malaria
antigen
suscept
broadli
neutral
antibodi
respons
follow
screen
ten
candid
antigen
rabbit
vaccin
recombin
vector
case
two
earlier
studi
fail
express
fulllength
recombin
protein
antigen
enabl
vaccin
test
contrast
vivo
mammalian
express
enabl
adenovir
poxvir
vector
abil
poxvir
vector
boost
prime
antibodi
respons
anim
thu
establish
number
difficult
diseas
target
ration
design
transgen
optim
vector
extens
report
although
seem
like
unlik
cell
induct
intracellular
antigen
process
present
antibodi
respons
reli
target
encod
antigen
secretori
pathway
achiev
use
ntermin
signal
peptid
human
tissu
plasminogen
activ
tpa
report
improv
antibodi
immunogen
dna
vaccin
recombin
vaccinia
viru
well
adenovirus
presum
allow
antigen
express
intracellularli
exit
infect
cell
engag
b
cell
receptor
intriguingli
though
studi
recombin
vaccinia
also
assess
merit
membranebind
versu
secret
encod
p
falciparum
antigen
report
highest
level
function
antibodi
induct
antigen
design
anchor
membran
similar
observ
made
show
target
protect
antigen
yersinia
pesti
imv
membran
vaccinia
viru
led
enhanc
protect
antibodi
respons
mice
benefit
membran
anchor
versu
secret
may
antigendepend
well
determin
cell
type
infect
observ
may
warrant
investig
new
poxvir
vector
design
optim
antibodi
induct
prolong
week
rather
week
primeboost
interv
also
report
essenti
hightitr
antibodi
induct
follow
immun
agreement
anoth
malaria
studi
use
vaccinia
viru
vector
express
sporozoitestag
circumsporozoit
protein
csp
interv
presum
allow
suffici
time
b
cell
prime
vector
contract
memori
phase
prior
effici
boost
nevertheless
even
longer
week
interv
report
mice
improv
igg
induct
use
mva
recombin
encod
p
falciparum
suggest
work
necessari
establish
optim
immun
schedul
compar
data
report
regard
antibodi
induct
poxvir
vector
choic
transgen
promot
insert
site
tk
locu
tradit
use
insert
transgen
cassett
along
site
larg
genom
delet
recent
intergen
region
promot
strength
highli
variabl
constitut
earli
andor
late
activ
commonli
use
promot
earlyl
activ
includ
short
synthet
promot
ssp
whilst
except
strong
intermediatel
promot
also
report
one
tumour
vaccin
studi
cell
induct
vaccinia
viru
shown
associ
overal
promot
activ
per
se
instead
earli
promot
activ
antigen
present
cell
recent
four
immediateearli
endogen
promot
util
authent
genom
loci
mva
shown
given
compar
cell
immunogen
convent
promot
use
tradit
insert
site
vivo
imag
studi
mice
util
vaccinia
mva
recombin
luciferas
also
shown
poxvir
vector
lead
shorter
burst
antigen
express
comparison
recombin
adenoviru
whilst
transgen
express
level
also
rout
immun
depend
merit
promot
activ
timingdur
antigen
express
remain
investig
regard
poxvir
antibodyinduc
capabl
especi
given
mani
antibodi
respons
reportedli
vaccin
dosedepend
studi
antibodi
induct
chimpanze
adenovir
vaccin
shown
sensit
type
interferon
ifn
induct
whether
mechan
also
affect
antibodi
induct
poxvir
vaccin
remain
explor
analys
shown
mva
stimul
innat
product
vitro
whilst
type
ifn
resist
reportedli
mediat
gene
product
much
better
understand
poxviru
vector
stimul
escap
host
immun
lead
new
way
explor
vector
modif
potenti
improv
antibodi
b
cell
immunogen
experi
report
clinic
trial
regard
antibodyinduc
capabl
recombin
poxvir
vector
vaccin
candid
given
progress
induc
cell
target
intracellular
pathogen
nevertheless
agreement
preclin
studi
earli
phase
ia
clinic
trial
malaria
field
report
limit
undetect
serum
igg
antibodi
respons
follow
immun
healthi
adult
volunt
uk
dnamva
regim
respect
encod
liverstag
malaria
antigen
metrap
multiepitop
string
fuse
thrombospondinrel
adhes
protein
differ
mva
vector
encod
csp
also
fail
prime
antibodi
respons
human
could
boost
particul
csp
proteininadjuv
vaccin
would
predict
preclin
studi
similarli
nyvac
vector
encod
seven
differ
antigen
p
falciparum
show
antibodi
induct
rhesu
macaqu
well
advantag
poxvir
deliveri
term
insert
capac
genotyp
stabil
howev
low
level
antibodi
induct
observ
phase
iiia
trial
three
homolog
immun
given
healthi
adult
encouragingli
phase
clinic
trial
use
alvac
vector
recombin
rabi
glycoprotein
g
show
neutral
serum
antibodi
induct
dosedepend
manner
although
titr
achiev
lower
follow
immun
standard
human
diploid
cell
cultur
rabi
vaccin
alvac
primeprotein
boost
regim
also
recent
report
induc
efficaci
phase
iii
clinic
trial
undertaken
thailand
induct
broadli
neutral
antibodi
report
howev
low
level
plasma
antienv
iga
high
level
igg
antibodi
capabl
bind
variabl
region
env
associ
reduc
infect
risk
secondari
analysi
low
level
antienv
iga
high
level
antibodi
associ
antibodydepend
cellular
cytotox
adcc
also
implic
thu
remain
clear
import
field
establish
whether
qualit
differ
antibodi
induct
occur
human
context
canarypox
viru
primeprotein
boost
regim
comparison
approach
elicit
quantit
improv
humor
immun
recent
phase
ia
clinic
trial
util
vector
design
secret
p
falciparum
infect
cell
shown
signific
promis
follow
immun
healthi
uk
adult
volunt
vector
subject
seroconvert
encod
transgen
administr
recombin
mva
vector
day
led
signific
boost
serum
igg
respons
predict
anim
model
case
antigen
standard
elisa
readout
show
peak
median
respons
equal
gml
antigenspecif
igg
encouragingli
case
antibodi
respons
compar
observ
protein
vaccin
formul
either
aluminium
hydroxid
alhydrogel
montanid
adjuv
assess
intern
refer
laboratori
howev
remain
lower
seen
protein
vaccin
administ
alhydrogel
adjuv
proprietari
formul
gsk
indic
remain
scope
improv
regard
vectorinduc
antibodi
immunogen
proteinbas
bloodstag
malaria
vaccin
demonstr
signific
efficaci
todat
primari
endpoint
phase
ii
clinic
trial
agreement
antibodi
induc
vector
vaccin
subsequ
fail
impact
bloodstag
malaria
parasit
growth
rate
phase
iia
efficaci
studi
wherebi
vaccin
individu
expos
five
infecti
mosquito
bite
howev
strong
cell
respons
induc
conjunct
antibodi
respons
appear
effect
bloodstag
parasit
form
develop
liver
thu
reduc
livertoblood
parasit
inoculum
lead
delay
malaria
diagnosi
subset
vaccine
steril
immun
one
despit
absenc
efficaci
afford
bloodstag
p
falciparum
parasit
use
vector
encod
remain
encourag
level
antibodi
induc
human
without
need
adjuv
recombin
protein
difficult
infecti
pathogen
like
suscept
antibodi
without
need
extrem
titr
may
suitabl
target
current
vector
vaccin
technolog
pneumococc
conjug
vaccin
exampl
believ
protect
invas
diseas
anticapsular
igg
concentr
exce
threshold
gml
well
within
scope
adenovirusmva
human
immun
two
clinic
report
also
suggest
reboost
cell
respons
mva
effect
earli
six
month
preced
immun
somewhat
encourag
subunit
vaccin
develop
potenti
concern
regard
longev
protect
might
afford
mva
thirdgener
smallpox
vaccin
remain
seen
whether
reboost
demonstr
regard
b
cell
antibodi
respons
given
rel
success
human
field
unsurpris
antibodyinduc
poxvir
vector
also
made
major
impact
field
veterinari
vaccin
inde
less
stringent
regulatori
requir
greater
eas
efficaci
assess
mean
least
nine
recombin
poxvir
vaccin
six
alvac
two
fowlpox
viru
fpv
one
vaccinia
viru
licens
veterinari
use
rang
viral
pathogen
rabi
viru
newcastl
diseas
viru
avian
equin
influenza
viru
west
nile
viru
canin
distemp
viru
felin
leukaemia
viru
addit
use
recombin
fpv
vaccin
poultri
provid
dual
protect
avian
pathogen
clear
advantag
term
vaccin
cost
effect
effect
target
viral
haemagglutinin
surfac
glycoprotein
mani
like
afford
protect
least
part
via
antibodi
induct
mirror
rel
success
poxvir
vaccin
induc
antibodi
respons
describ
earlier
human
pathogen
adjuvant
viral
vector
vaccin
prove
straightforward
given
inher
immunogen
natur
viral
vector
howev
report
demonstr
potenti
improv
quantit
antibodi
immunogen
fusion
oligomer
domain
complement
protein
cterminu
encod
protein
lead
express
heptamer
antigen
shown
lead
minor
improv
antibodi
induct
malaria
antigen
follow
primeboost
immun
well
follow
mvamva
homolog
regim
coadministr
classic
oilinwat
emuls
adjuv
also
shown
improv
antibodi
induct
pig
nyvac
vector
encod
ha
avian
influenza
similarli
addit
carbopol
polym
alvac
vector
encod
glycoprotein
equin
herp
led
improv
antibodi
immunogen
protect
poni
furthermor
mva
poxvir
vaccin
also
report
act
adjuv
mice
protein
vaccin
malaria
csp
antigen
whilst
mva
nyvac
alvac
also
shown
adjuv
hbsag
similar
manner
numer
exampl
avail
describ
antibodyinduc
capabl
poxvir
vaccin
vector
anim
human
includ
induct
strong
antipoxvir
respons
well
encod
transgen
clear
antigendepend
relat
eas
antibodi
induct
perform
well
context
poxviralonli
regim
wherea
case
poxviru
function
effect
antibodyboost
platform
success
veterinari
field
led
numer
licens
product
promis
data
also
emerg
numer
clinic
trial
regard
poxvir
vector
fulfil
role
context
antibodi
induct
howev
remain
clear
scope
improv
signific
effort
need
better
understand
mechan
paramet
vector
affect
b
cell
prime
boost
poxvir
vector
longer
view
vaccin
develop
mean
exclus
cell
induct
instead
care
design
applic
also
regard
robust
versatil
tool
induct
antibodi
